BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib

Highlights • Somatic BRAF mutations have been reported in 1–4% of non-small cell lung cancers. • Our patient had NSCLC with metastases to her brain with the BRAF (V600E) mutation. • Vemurafenib, a BRAF inhibitor approved for use in metastatic melanoma, was used. • Vemurafenib was active against intr...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2014-08, Vol.85 (2), p.326-330
Main Authors: Robinson, Sara D, O'Shaughnessy, Joyce A, Lance Cowey, C, Konduri, Kartik
Format: Article
Language:English
Subjects:
Adenocarcinoma - diagnosis
Adenocarcinoma - genetics
Adenocarcinoma - pathology
Adenocarcinoma of Lung
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Biopsy
BRAF mutation
Brain metastasis
Brain Neoplasms - diagnosis
Brain Neoplasms - drug therapy
Brain Neoplasms - secondary
Female
Hematology, Oncology and Palliative Medicine
High-Throughput Nucleotide Sequencing
Humans
Indoles - therapeutic use
Lung adenocarcinoma
Lung Neoplasms - diagnosis
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Lymph Nodes - pathology
Magnetic Resonance Imaging
Medical sciences
Middle Aged
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Mutation
Neurology
Non-small cell lung cancer
Pneumology
Protein Kinase Inhibitors - therapeutic use
Proto-Oncogene Proteins B-raf - genetics
Pulmonary/Respiratory
Sulfonamides - therapeutic use
Targeted therapy
Tomography, X-Ray Computed
Treatment Outcome
Tumors
Tumors of the nervous system. Phacomatoses
Tumors of the respiratory system and mediastinum
Vemurafenib
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Somatic BRAF mutations have been reported in 1–4% of non-small cell lung cancers. • Our patient had NSCLC with metastases to her brain with the BRAF (V600E) mutation. • Vemurafenib, a BRAF inhibitor approved for use in metastatic melanoma, was used. • Vemurafenib was active against intracranial metastases from this patient's NSCLC.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2014.05.009